Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Chuankang Pharmaceutical Co., Ltd. (Sinopharm Chuankang for short), a holding subsidiary of the company, received the “Drug GMP Compliance Inspection Notice” issued by the Sichuan Drug Administration. The workshop and production line involved in this GMP compliance inspection, Fine Baking Package 2 (active ingredient (tacrolimus) production line) was newly opened after the production line was remodeled. Currently, the product produced is the active ingredient (tacrolimus), and the design production capacity is 100 kg/year.

This time, the Sinopharm Chuankang production line passed the pharmaceutical GMP compliance inspection after being upgraded, indicating that the production line and production process meet the requirements of the “Pharmaceutical Production Quality Management Code (2010 Revision)”, which helps the company expand the production capacity scale of APIs in the immunosuppressant sector, promote the integrated development of the API formulation industry chain, and better meet the market demand for related drugs. The above matters will not have a significant impact on the company's current operating results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.